The Bevacizumab Biosimilars Global Market Report 2023, provides comprehensive information on the bevacizumab biosimilars market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032
Learn More On The Bevacizumab Biosimilars Market’s Growth:
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
The global bevacizumab biosimilars market size is expected to grow from $1.31 billion in 2022 to $1.43 billion in 2023 at a compound annual growth rate (CAGR) of 9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global bevacizumab biosimilars market size is expected to reach $1.93 billion in 2027 at a CAGR of 7.9%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=10848&type=smp
Product innovation has emerged as a key trend gaining popularity in the bevacizumab biosimilars market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, launched a biosimilar called Abevmy® (bevacizumab), which is a biosimilar similar to Roche’s Avastin® (bevacizumab). Abevmy has received approval from Health Canada for use across four oncology indications. The product offers efficacy, safety, and quality similar to the reference biologic, as it is a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF).
The bevacizumab biosimilars market is segmented:
1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer
North America was the largest region in the bevacizumab biosimilars market in 2022.
Top 5 Major Key Players Are:
Hetero Drugs Ltd
Amgen Inc
Biocon Ltd
Mylan Inc
BioXpress Therapeutics SA
Table Of Contents
1. Executive Summary
2. Bevacizumab Biosimilars Market Characteristics
3. Bevacizumab Biosimilars Market Trends And Strategies
4. Bevacizumab Biosimilars Market – Macro Economic Scenario
5. Bevacizumab Biosimilars Market Size And Growth
…….
26. Africa Bevacizumab Biosimilars Market
27. Bevacizumab Biosimilars Market Competitive Landscape And Company Profiles
The medium power transformers global market report 2024 from The Business Research Company provides comprehensive…
The medical and diagnostic laboratory services global market report 2024 from The Business Research Company…
The legal software (focus on machine learning) global market report 2024 from The Business Research…
The integrated geophysical services global market report 2024 from The Business Research Company provides comprehensive…
The immunochemistry diagnostic devices and equipment global market report 2024 from The Business Research Company…
The high voltage switchgear global market report 2024 from The Business Research Company provides comprehensive…